Wall Street brokerages expect Adaptimmune Therapeutics PLC (NASDAQ:ADAP) to post earnings per share of ($0.24) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Adaptimmune Therapeutics PLC’s earnings, with estimates ranging from ($0.31) to ($0.18). Adaptimmune Therapeutics PLC posted earnings per share of ($0.31) in the same quarter last year, which indicates a positive year over year growth rate of 22.6%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Adaptimmune Therapeutics PLC will report full year earnings of ($0.99) per share for the current financial year, with EPS estimates ranging from ($1.30) to ($0.76). For the next financial year, analysts forecast that the business will report earnings of ($1.01) per share, with EPS estimates ranging from ($1.28) to ($0.59). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Adaptimmune Therapeutics PLC.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last issued its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.06. Adaptimmune Therapeutics PLC had a negative return on equity of 41.40% and a negative net margin of 550.22%. The business had revenue of $2.86 million during the quarter, compared to the consensus estimate of $5.07 million.

Several research firms recently issued reports on ADAP. BidaskClub upgraded Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Saturday. Cowen and Company reiterated a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. Finally, Wells Fargo & Company began coverage on Adaptimmune Therapeutics PLC in a report on Friday, March 17th. They issued a “market perform” rating on the stock. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $11.83.

Shares of Adaptimmune Therapeutics PLC (NASDAQ ADAP) traded down 0.63% during midday trading on Tuesday, reaching $4.75. 203,064 shares of the company’s stock traded hands. Adaptimmune Therapeutics PLC has a 52-week low of $3.76 and a 52-week high of $9.09.

A number of institutional investors have recently added to or reduced their stakes in ADAP. Raymond James Financial Services Advisors Inc. bought a new position in Adaptimmune Therapeutics PLC during the first quarter valued at $120,000. KCG Holdings Inc. bought a new position in Adaptimmune Therapeutics PLC during the first quarter valued at $133,000. Monashee Investment Management LLC bought a new position in Adaptimmune Therapeutics PLC during the first quarter valued at $138,000. Paloma Partners Management Co bought a new position in Adaptimmune Therapeutics PLC during the first quarter valued at $165,000. Finally, Creative Planning raised its position in Adaptimmune Therapeutics PLC by 32.8% in the first quarter. Creative Planning now owns 40,500 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 10,000 shares during the last quarter. 56.15% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/07/11/adaptimmune-therapeutics-plc-adap-expected-to-post-earnings-of-0-24-per-share.html.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Get a free copy of the Zacks research report on Adaptimmune Therapeutics PLC (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.